Cyclosporine A-Loaded Solid Lipid Nanoparticles: Ocular Tolerance and In Vivo Drug Release in Rabbit Eyes

REFERENCES

• Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery Adv Drug Del Rev. 1995;16:3–19.
   Web of Science ®Google Scholar
• Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res. 2004;21:641–648.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Claudio B, Piera F, Adriana M, Antonina P, Giovanni P. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Biopharm. 2002;16:53–61.
   Google Scholar
• Zhang W, Prausnitz MR, Edwards A. Model of transient drug diffusion across cornea. J Control Rel. 2004;99:241–258.
   PubMed Web of Science ®Google Scholar
• Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems—Recent advances. Progr Retinal Eye Res. 1998;17:33–58.
   PubMed Web of Science ®Google Scholar
• Ding S. Recent developments in ophthalmic drug delivery. PSTT. 1998;1:328–335.
   Google Scholar
• Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Rel. 2009; doi:10.1016/j.jconrel.2008.12.018
   PubMed Web of Science ®Google Scholar
• Barbu E, Verestiuc L, Nevell TG, Tsibouklis J. Polymeric materials for ophthalmic drug delivery: Trends and perspectives. J Mater Chem. 2006;16:3439–3443.
   Web of Science ®Google Scholar
• Ueda NH, Akimoto M, Natsume H, Morimoto Y. Ability of poly-L-arginine to enhance drug absorption into aqueous humor and vitreous body after instillation in rabbits. Biol Pharm Bull. 2007;30:1768–1772.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247–3255.
   PubMed Web of Science ®Google Scholar
• Zimmer AK, Serbe H, Kreuter J. Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye. I. In vitro and in vivo characterization. J Control Rel. 1994;32:57–70.
   Web of Science ®Google Scholar
• Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm. 1997;153:41–50.
   Web of Science ®Google Scholar
• Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340:126–133.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–318.
   PubMed Web of Science ®Google Scholar
• Kuwano M, Ibuki H, Morikawa N, Ota A, Kawashima Y. Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm Res. 2002;19:108–111.
   PubMed Web of Science ®Google Scholar
• Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;46:953–1040.
   Web of Science ®Google Scholar
• Italia JL, Bhardwaj V, Kumar MN. Disease, destination, dose, and delivery aspects of cyclosporin: The state of the art. Drug Discov Today. 2006;11:846–854.
   PubMed Web of Science ®Google Scholar
• Calvo P, Sánchez A, Martínez J, López MI, Calonge M, Pastor JC, Alonso MJ. Polyester nanocapsules as a new topical ocular delivery system for cyclosporine A. Pharm Res. 1996;13:311–315.
   PubMed Web of Science ®Google Scholar
• Alonso MJ, Calvo P, Vila-Jato JL, López MI, Llorente J, Pastor JC. Increased ocular corneal uptake of drugs using poly-ϵ-caprolactone nanocapsules and nanoemulsions. In: Proc Int Symp Control Rel Bioact Mater. 1995;22.
   Google Scholar
• Le Bourlais C, Chevarme F, Turlin B, Acar L, Zia H, Sado PA, Necdham TE, Leverge R. Effect of cyclosporine A formulations on bovine corneal absorption: Ex vivo study. J Microencapsul. 1997;14:457–467.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: A review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization, and applications. Adv Drug Deliv Rev. 2001;47:165–196.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238:241–245.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Morel S, Gasco MR, Chetoni P, Saettone MF. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int J Pharm. 1995;117:243–246.
   Web of Science ®Google Scholar
• Jenning V, Gohla S. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 2001;18:149–158.
   PubMed Web of Science ®Google Scholar
• Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Meth Find Exp Clin Pharmacol. 2005;27:127–144.
   PubMed Web of Science ®Google Scholar
• Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm. 2002;241:341–344.
   PubMed Web of Science ®Google Scholar
• Husek A. High performance liquid chromatography cyclosporin A and its oral solution. J Chrom A. 1997;759:217–224.
   PubMed Web of Science ®Google Scholar
• Baeyens V, Felt-Baeyens O, Rougier S, Pheulpin S, Boisrame B, Gurny R. Clinical evaluation of bioadhesive ophthalmic drug inserts (BODI) for the treatment of external ocular infections in dogs. J Control Rel. 2002;85:163–168.
   PubMed Web of Science ®Google Scholar
• Ciofani G, Rafa V, Menciassi A, Dario P. Alginate and chitosan particles as drug delivery system for cell therapy. Biomed Microdevices. 2008;10:131–140.
   PubMed Web of Science ®Google Scholar
• Giunchedi P, Conte U, Chetoni P, Saettone MF. Pectin microspheres as ophthalmic carriers for piroxicam: Evaluation in vitro and in vivo in albino rabbits. Eur J Pharm Sci. 1999;9:1–7.
   PubMed Web of Science ®Google Scholar
• Van Der Bijl P, Engelbrecht AH, Van Eyk AD, Meyer D. Comparative permeability of human and rabbit corneas to cyclosporin and tritiated water. J Ocular Pharm Ther. 2002;18:419–427.
   PubMed Web of Science ®Google Scholar
• Yeh MK, Tung SM, Lu DW, Chen JL, Chiang CH. Formulation factors for preparing ocular biodegradable delivery system of 5-fluorouracil microparticles. J Microencapsul. 2001;18:507–519.
   PubMed Web of Science ®Google Scholar
• Hachicha W, Kodjikian L, Fessi H. Preparation of vancomycin microparticles: Importance of preparation parameters. Int J Pharm. 2006;324:176–184.
   PubMed Web of Science ®Google Scholar
• Wilson CG. Assessing ocular drug delivery with lachrimal scintigraphy. PSTT. 1999;2:321–326.
   PubMedGoogle Scholar
• He Y, Liu Y, Liu Y, Wang J, Zhang X, Lu W, Ma Z, Zhu X, Zhang Q. Cyclosporine-loaded microspheres for treatment of uveitis: In vitro characterization and in vivo pharmacokinetic study. IOVS. 2006;47:9.
   Web of Science ®Google Scholar
• Salamanca AE, Diebold Y, Calonge M, Garcia-Vazquez C, Callejo S, Vila A, Alonso MJ. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism, and in vivo tolerance. IOVS. 2006;47:4.
   Web of Science ®Google Scholar
• Acheampong AA, Shackleton M, Tang-Liu DD, Ding S, Stern ME, Decker R. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res. 1999;18:91–103.
   PubMed Web of Science ®Google Scholar
• Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Güneri T, Caramella C. Cyclosporine A-loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008;364:76–86.
   PubMed Web of Science ®Google Scholar
• Svendsen A. Lipase protein engineering. Biochim Biophys Acta. 2000;1543:223–228.
   PubMed Web of Science ®Google Scholar
• Elner VM. Retinal pigment epithelial acid lipase activity and lipoprotein receptors: Effects of dietary omega-3 fatty acids. Trans Am Ophthalmol Soc. 2002;100:301–338.
   PubMedGoogle Scholar
• Zimmer A, Kreuter J, Robinson JR. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J Microencapsul. 1991;8:497–504.
   PubMed Web of Science ®Google Scholar
• López-Miranda J, Pérez-Jiménez F, Gómez-Gerique JA, Espino-Montoro A, Hidalgo-Rojas L, Pedreño J, Jiménez-Perepérez JA. Effect of cyclosporin on plasma lipoprotein lipase activity in rats. Clin Biochem. 1992;25:387–394.
   PubMed Web of Science ®Google Scholar
• Atama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008;355:307–313.
   PubMedGoogle Scholar
• Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57:1595–1639.
   PubMed Web of Science ®Google Scholar
• Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharm Physiol. 2000;27:558–562.
   PubMed Web of Science ®Google Scholar
• Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. AAPS PharmSciTech. 2005;7:E820–833.
   Google Scholar
• Toropainen E, Ranta VP, Vellonen KS, Palmgrén J, Talvitie A, Laavola M, Suhonen P, Hämäläinen KM, Auriola S, Urtti A. Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model. Eur J Pharm Biopharm. 2003;20:99–106.
   Google Scholar
• Rojanasakul Y, Wang LY, Bhat M, Glover DD, Malanga CJ, Ma JKM. The transport barrier of epithelia: A comparative study on membrane permeability and charge selectivity in the rabbit. Pharm Res. 1992;9:1029–1034.
   PubMed Web of Science ®Google Scholar
• De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224:159–168.
   PubMedGoogle Scholar
• Hamdani J, Moes AJ, Amighi K. Physical and thermal characterization of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm. 2003;260:47–57.
   PubMed Web of Science ®Google Scholar
• Xia Q, Saupe A, Müller RH, Souto EB. Nanostructured lipid carriers as novel carrier for sunscreen formulations. Int J Cosmet Sci. 2007;29:473–482.
   PubMed Web of Science ®Google Scholar
• Hutak CM, Jacaruso RB. Evaluation of primary ocular irritation: Alternatives to the Draize test. In: Reddy IK, ed. Ocular Therapeutics and Drug Delivery.. Lancaster, PA: Technomic Publishing; 1996: 489–525.
   Google Scholar
• Bowers LD, Canafax DM. Cyclosporin: Experience with therapeutic monitoring. Ther Drug Monit. 1984;6:142–147.
   PubMed Web of Science ®Google Scholar